Hematological cancers like non-Hodgkin's lymphoma have seen a revolution in care due to the advances of targeted cell therapies like CAR-T. However, not all blood cancers have enjoyed the same benefit, hampered by the lack of actionable and specific blood cell targets.
Stanford researchers have suggested ganglioside GM2, which is upregulated with the loss of ganglioside GD2, as a safe alternative target for antibodies and CAR-T cells for cancer immunotherapy.
Stanford researchers have suggested targeting ganglioside GM2, either alone or in combination with ganglioside GD2, to enhance CAR-T therapy for cancer.
Stanford scientists have developed fully human CD19-targeted CAR T cells designed to overcome the limitations of current CAR T cell therapies, particularly in treating low CD19 density blood cancers.
Stanford researchers have developed a highly effective B7-H3 chimeric antigen receptor (CAR) for CAR-T cell therapy, designed to enhance binding and cytotoxicity against B7-H3 expressing solid tumors, offering a promising treatment for various cancers.
Researchers in Prof. Crystal Mackall's laboratory at Stanford University are focused on translational research related to cancer immunotherapy, including basic T-cell function and tumor immunology.
Stanford researchers have engineered chimeric cytokine receptors that are expressed in therapeutic cells to enhance their activity and therapeutic potential.
Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.
Researchers at Stanford have developed chimeric antigen receptors (CARs) that target glypican-2 (GPC2) and can be used to treat solid tumors. CAR-engineered T cells have shown great promise as cancer therapeutics.